In Brief This Week: Ariosa Diagnostics; Abbott; Quidel; Precision BioSciences, Cellectis; Vermillion; Rosetta Genomics; BGI; NeoGenomics; Warnex; ClearBridge BioMedics | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Ariosa Diagnostics, formerly known as Aria Diagnostics, said this week that it has completed clinical validation of its Harmony Prenatal Test for non-invasive detection of common fetal trisomies and announced the first medical facility to offer the test. The San Jose, Calif.-based firm said that Atlanta Perinatal Consultants at Northside Hospital in Atlanta is the first to offer the test, which will "become more broadly available in the near future."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.